Proton Treatment Suppresses Exosome Production in Head and Neck Squamous Cell Carcinoma.

HNSCC IFN-γ cancer immunology exosomes head and neck cancers photon therapy proton therapy radiation therapy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
29 Feb 2024
Historique:
received: 24 01 2024
revised: 23 02 2024
accepted: 26 02 2024
medline: 13 3 2024
pubmed: 13 3 2024
entrez: 13 3 2024
Statut: epublish

Résumé

Proton therapy (PT) is emerging as an effective and less toxic alternative to conventional X-ray-based photon therapy (XRT) for patients with advanced head and neck squamous cell carcinomas (HNSCCs) owing to its clustered dose deposition dosimetric characteristics. For optimal efficacy, cancer therapies, including PT, must elicit a robust anti-tumor response by effector and cytotoxic immune cells in the tumor microenvironment (TME). While tumor-derived exosomes contribute to immune cell suppression in the TME, information on the effects of PT on exosomes and anti-tumor immune responses in HNSCC is not known. In this study, we generated primary HNSCC cells from tumors resected from HNSCC patients, irradiated them with 5 Gy PT or XRT, and isolated exosomes from cell culture supernatants. HNSCC cells exposed to PT produced 75% fewer exosomes than XRT- and non-irradiated HNSCC cells. This effect persisted in proton-irradiated cells for up to five days. Furthermore, we observed that exosomes from proton-irradiated cells were identical in morphology and immunosuppressive effects (suppression of IFN-γ release by peripheral blood mononuclear cells) to those of photon-irradiated cells. Our results suggest that PT limits the suppressive effect of exosomes on cancer immune surveillance by reducing the production of exosomes that can inhibit immune cell function.

Identifiants

pubmed: 38473367
pii: cancers16051008
doi: 10.3390/cancers16051008
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NIH HHS
ID : 5 R21 CA 277341-02
Pays : United States

Auteurs

Ameet A Chimote (AA)

Division of Nephrology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.

Maria A Lehn (MA)

Division of Hematology-Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.

Jay Bhati (J)

Division of Nephrology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.

Anthony E Mascia (AE)

Department of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.

Mathieu Sertorio (M)

Department of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.

Michael A Lamba (MA)

Department of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.

Dan Ionascu (D)

Department of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.

Alice L Tang (AL)

Department of Otolarynogology, Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.

Scott M Langevin (SM)

Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA.
University of Vermont Cancer Center, Burlington, VT 05405, USA.

Marat V Khodoun (MV)

Division of Rheumatology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.

Trisha M Wise-Draper (TM)

Division of Hematology-Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.

Laura Conforti (L)

Division of Nephrology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.

Classifications MeSH